Teva reported success in a gluten challenge study for an experimental antibody, saying a single injection significantly reduced intestinal damage in celiac disease patients after they ate gluten daily. The company framed the topline as statistically significant and clinically meaningful versus placebo over eight weeks. The results arrive in a competitive first-to-market race, with Teva positioning TEV-408 as a pipeline-in-a-product candidate. The company noted that analyses from an ongoing Phase 2a study are underway and that additional data will be presented at a future meeting. For autoimmune drug developers, gluten challenge designs remain a high-scrutiny way to demonstrate target engagement and clinically relevant mucosal outcomes—important for eventual regulator and payor confidence.